Aura Biosciences, Inc.

NASDAQ:AURA

Biotechnology

Healthcare
$7.14 -1.43%

-$0.09 today

Market cap
$743.09M
Beta
0.39
P/E (TTM)
-3.7
EPS (TTM)
-$1.67
52W Low $4.73High $9.54

Volume 0.69M

Average 0.52M

AURA Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Aura Biosciences, Inc.NASDAQ: AURA

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation grows, but more slowly than its trailing trend

Q1 FY2026 stock-based compensation of $3.82M rose 8.8% year over year, behind the +18.7% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 16.5% from the prior quarter. Over 3 fiscal years it compounded at +30.7% a year.

Context

  • Stock-based compensation increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +8.8% toward the trailing-twelve-month pace of +18.7%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$3.82M+16.5% QoQ
Last fiscal yearDec 2025
$14.32M+22.1% YoY
LTMMar 2026
$14.63M+18.7% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+8.8%——
1 year+22.1%——
3-year CAGR+30.7%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
14.32M USD
Year-over-year change
+22.1%
4-year CAGR
+57.8%

Stock-Based Compensation vs competitors

How AURA compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +18.7% is the 5th highest of 11, against a peer median of -3.1%.
  • Over three fiscal years its annual growth of +30.7% compares with a peer median of +9.3%.
AURA Competitors
Stock-Based Compensation for AURA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IMNMImmunome, Inc.LTM Sep 2026$37.41M USD+60.8%+68.9%—
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 2026$31.69M USD-0.5%+25.3%416.2%
OCSOculis Holding AGLTM Mar 2026CHF 18.42M CHF+63.4%+171.2%3653.8%
AURAAura Biosciences, Inc.LTM Mar 2026$14.63M USD+18.7%+30.7%—
MGNXMacroGenics, Inc.LTM Mar 2026$12.55M USD-55.6%-11.3%8.0%
WHWKWhitehawk Therapeutics IncLTM Dec 2025$9.87M USD-8.9%+0.8%138.2%
OCGNOcugen, Inc.LTM Mar 2026$9.22M USD+22.1%-9.9%206.5%
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$6.49M USD-5.6%+3.2%—
OTLKOutlook Therapeutics, Inc.LTM Mar 2026$5.14M USD-37.3%+4.9%1543.3%
AKTSAktis Oncology, Inc.FY2025$5.13M USD+127.0%+94.4%79.0%
BCYCBicycle Therapeutics plcLTM Mar 2026$2.68M USD-107.0%+13.8%4.2%
Peer median (excluding AURA) —-3.1%+9.3%172.3%

Competitors are the stored peer set for AURA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(35.25M)(58.76M)(76.41M)(86.92M)(106.19M)
Depreciation & Amortization831K1.18M1.3M1.22M1.13M
Deferred Income Tax14K0000
Stock-Based Compensation2.31M6.41M8.77M11.72M14.32M
Change in Working Capital(315K)(3.1M)4.44M(2.64M)5.97M
Accounts Receivables00000
Inventory00000
Accounts Payables1.05M340K(1.04M)482K(846K)
Other Working Capital(1.37M)(3.44M)5.48M(3.12M)6.82M
Other Non-Cash Items4K(325K)(1.95M)(3.19M)32K
Operating Cash Flow(32.41M)(54.6M)(63.85M)(79.81M)(84.74M)
Capital Expenditures(2.13M)(1.09M)(709K)(1.25M)(447K)
Acquisitions (Net)066.78K000
Purchases of Investments0(119.78M)(233.65M)(59.11M)(83.96M)
Sales of Investments053.01M120.4M129.18M120M
Other Investing Activities0(66.78K)000
Investing Cash Flow(2.13M)(67.87M)(113.96M)68.82M35.6M
Debt Repayment00000
Common Stock Issued78.7M8.55M3.17M1.6M77.16M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities334K430K1.5M00
Financing Cash Flow166.26M95.63M97.29M1.6M77.16M
Effect of Forex Changes0000(186K)
Net Change in Cash131.72M(26.84M)(80.52M)(9.39M)27.82M
Free Cash Flow(34.54M)(55.7M)(64.56M)(81.06M)(85.19M)

Aura Biosciences, Inc.

NASDAQ:AURA

Intrinsic Alpha fair value

Locked

Current Price

$7.14

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.